ClinicalTrials.gov
ClinicalTrials.gov Menu

A Web-based Study of Quality of Life Benefits Associated Aranesp in Anemic Patients With Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00153868
Recruitment Status : Active, not recruiting
First Posted : September 12, 2005
Last Update Posted : June 28, 2016
Sponsor:
Collaborator:
Amgen
Information provided by (Responsible Party):
Dartmouth-Hitchcock Medical Center

Brief Summary:
This is a web-based pilot study to evaluate the association between the treatment of anemia with darbepoetin alfa (aranesp) and the clinical benefits in symptom palliation, improved functional status and quality of life in patients with cancer. The feasibility of web-based assessments and data capture will be evaluated.

Condition or disease Intervention/treatment Phase
Anemia Cancer Drug: darbepoetin alfa Not Applicable

Detailed Description:
Anemia associated with lung cancer and chemotherapy is an important factor effecting patient symptoms, functional status, and overall quality of life (Groopman and Itri 1999; Langer, Choy et al. 2002). Darbepoetin alfa (Aranesp®) has demonstrated a significant effect upon ameliorating chemotherapy-induced anemia in lung cancer (Vansteenkiste, Pirker et al. 2002; Vansteenkiste, Poulsen et al. 2002). This trial is designed to evaluate the association between the treatment of anemia with darbepoetin alfa and direct electronic capture of clinical benefits in cancer-related symptoms, functional status and overall quality of life. This trial uses a secure web-based design to capture the patient-associated symptoms, functional status and quality of life. This novel secure web-based system was selected to improve the efficiency and quality of clinical data capture. If our hypothesis is correct, treatment with darbepoetin alfa will be associated with improved palliation of cancer-related symptoms, improved functional status, and result in overall benefits to the patient's health-related quality of life. The development of a web-based system to directly capture patient-related symptoms, functional status and quality of life will permit us in the future to conduct a national or international trial addressing the effects of darbepoetin alfa on these factors. If our hypothesis is incorrect, it may be that these parameters are not affected by the correction of anemia with darbepoetin alfa or the measures are not sensitive enough to detect these differences. A notable finding would be a clearly defined improvement in symptom palliation, functional status, and quality of life associated with darbepoetin alfa therapy.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 43 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Pilot Web-based Study of Functional Status, Symptom Palliation and Quality of Life Benefits Associated With Darbepoetin Alfa (Aranesp®) Administration in Anemic Patients With Cancer.
Study Start Date : October 2003
Estimated Primary Completion Date : December 2025
Estimated Study Completion Date : December 2025

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Active Comparator: 1
Darbepoetin alfa 200 mcg with escalation to 300 mcg after 6 weeks (week 7 dose) for non-responders subcutaneously every 2 weeks for 12 weeks (weeks 1, 3, 5, 7, 9, and 11)
Drug: darbepoetin alfa
The allocation to the treatment arms will be dependent on the schedule of chemotherapy (i.e. weekly, every 2 week, or every 4 week chemotherapy schedules will receive a starting dose of 200 mcg darbepoetin alfa and every 3 week chemotherapy schedule will receive a starting dose of 300 mcg). Non-responders are defined as patients who experience <1.0 g/dL increase in hemoglobin concentrations after 6 weeks. Darbepoetin alfa will be held for hemoglobin concentrations >13.0 g/dL.
Other Name: aranesp

Active Comparator: 2
darbepoetin alfa 300 mcg with escalation to 500 mcg after 6 weeks (week 7 dose) for non-responders subcutaneously every 3 weeks for 12 weeks (weeks 1, 4, 7, and 10)
Drug: darbepoetin alfa
The allocation to the treatment arms will be dependent on the schedule of chemotherapy (i.e. weekly, every 2 week, or every 4 week chemotherapy schedules will receive a starting dose of 200 mcg darbepoetin alfa and every 3 week chemotherapy schedule will receive a starting dose of 300 mcg). Non-responders are defined as patients who experience <1.0 g/dL increase in hemoglobin concentrations after 6 weeks. Darbepoetin alfa will be held for hemoglobin concentrations >13.0 g/dL.
Other Name: aranesp




Primary Outcome Measures :
  1. A secure web-based assessment of cancer-related symptoms (LCSS), functional status (SF-36), and quality of life (FACT-An and PFS) will be obtained every 2 weeks (weeks 3, 5, 7, 9, 11, and 13). [ Time Frame: every 2 weeks (weeks 3, 5, 7, 9, 11, and 13) ]

Secondary Outcome Measures :
  1. A blood sample will be obtained to evaluate hemoglobin concentrations every 2 weeks (weeks 3, 5, 7, 9, 11, and 13). [ Time Frame: every 2 weeks (weeks 3, 5, 7, 9, 11, and 13) ]
  2. A blood sample will be obtained to evaluate plasma cytokines every 4 weeks (weeks 5, 9, and 13). [ Time Frame: every 4 weeks (weeks 5, 9, and 13) ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Confirmation of non-myeloid cancer (myeloproliferative disorders will be excluded).
  • Hemoglobin concentration ≤ 11.0 g/dL.
  • Age ≥ 18 years.
  • Karnofsky performance status ≥ 60%.
  • Anemia predominantly due to cancer or chemotherapy.
  • Serum creatinine concentration ≤ 2.0 mg/dL.
  • Total serum bilirubin ≤ 1.5 times the upper limit of normal.
  • Nutritional status adequate to provide vitamin B12 and folate within the normal limits.
  • Capacity to complete the web-based functional status, symptom and quality of life assessments.
  • Ability to give informed consent.

Exclusion Criteria:

  • Untreated symptomatic primary or metastatic cancer involving the central nervous system.
  • History of clinically significant iron deficiency.
  • Greater than two red blood cell transfusions within 2 weeks of registration or any red blood cell transfusion within 7 days of registration.
  • Received epoetin alfa or darbepoetin alfa therapy within 3 weeks prior to randomization.
  • History of a seizure disorder.
  • Unstable angina, congestive heart failure (New York Heart Association > class II or known ejection fraction < 40%) or uncontrolled cardiac arrhythmias.
  • Uncontrolled hypertension defined as a diastolic blood pressure > 100 mmHg.
  • Clinical evidence of active infection or inflammatory diseases such as rheumatoid arthritis. Subjects with active rheumatoid arthritis are excluded.
  • Known positive test for human immunodeficiency virus infection.
  • Known primary hematological disorder which could cause anemia such as sickle cell anemia.
  • Pregnant or breast-feeding.
  • Not using adequate contraception if of childbearing potential.
  • Known hypersensitivity to any recombinant mammalian-derived product.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00153868


Locations
United States, New Hampshire
Norris Cotton Cancer Center
Lebanon, New Hampshire, United States, 03756
Sponsors and Collaborators
Dartmouth-Hitchcock Medical Center
Amgen
Investigators
Principal Investigator: James R Rigas, MD Norris Cotton Cancer Center

Responsible Party: Dartmouth-Hitchcock Medical Center
ClinicalTrials.gov Identifier: NCT00153868     History of Changes
Other Study ID Numbers: D-0341
First Posted: September 12, 2005    Key Record Dates
Last Update Posted: June 28, 2016
Last Verified: June 2016

Keywords provided by Dartmouth-Hitchcock Medical Center:
Anemia
Cancer
Quality of life
Web-based
Aranesp
Darbepoetin alfa

Additional relevant MeSH terms:
Darbepoetin alfa
Hematinics